Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib extension study in CML and Ph+ ALL
NCT01279473Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2005
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nilotinib in chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), sponsored by Novartis. Started Aug 2005; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01279473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01279473.